These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28453552)
1. Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma. Benavides-Serrato A; Lee J; Holmes B; Landon KA; Bashir T; Jung ME; Lichtenstein A; Gera J PLoS One; 2017; 12(4):e0176599. PubMed ID: 28453552 [TBL] [Abstract][Full Text] [Related]
2. Significance of filamin A in mTORC2 function in glioblastoma. Chantaravisoot N; Wongkongkathep P; Loo JA; Mischel PS; Tamanoi F Mol Cancer; 2015 Jul; 14():127. PubMed ID: 26134617 [TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness. Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128 [TBL] [Abstract][Full Text] [Related]
4. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674 [TBL] [Abstract][Full Text] [Related]
7. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). García-Martínez JM; Alessi DR Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875 [TBL] [Abstract][Full Text] [Related]
8. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820 [TBL] [Abstract][Full Text] [Related]
9. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma. Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166 [TBL] [Abstract][Full Text] [Related]
10. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. Lee SL; Chou CC; Chuang HC; Hsu EC; Chiu PC; Kulp SK; Byrd JC; Chen CS PLoS One; 2013; 8(6):e67149. PubMed ID: 23840605 [TBL] [Abstract][Full Text] [Related]
11. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin. Zou Z; Chen J; Yang J; Bai X Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881 [TBL] [Abstract][Full Text] [Related]
12. XPLN is an endogenous inhibitor of mTORC2. Khanna N; Fang Y; Yoon MS; Chen J Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15979-84. PubMed ID: 24043828 [TBL] [Abstract][Full Text] [Related]
13. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma. Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046 [TBL] [Abstract][Full Text] [Related]
14. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation. Koo J; Wu X; Mao Z; Khuri FR; Sun SY J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075 [TBL] [Abstract][Full Text] [Related]
15. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880 [TBL] [Abstract][Full Text] [Related]
16. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870 [TBL] [Abstract][Full Text] [Related]
17. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906 [TBL] [Abstract][Full Text] [Related]
18. Transmembrane Inhibitor of RICTOR/mTORC2 in Hematopoietic Progenitors. Lee D; Sykes SM; Kalaitzidis D; Lane AA; Kfoury Y; Raaijmakers MH; Wang YH; Armstrong SA; Scadden DT Stem Cell Reports; 2014 Nov; 3(5):832-40. PubMed ID: 25418727 [TBL] [Abstract][Full Text] [Related]
19. Identification of rictor as a novel substrate of Polo-like kinase 1. Shao T; Liu X Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006 [TBL] [Abstract][Full Text] [Related]
20. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]